Inari Medical EBIT

The latest EBIT for NARI is $-37M as of September 2024. That compares with $1.7M in the prior-year period — down 2322.2% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Inari Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, NARI's EBIT moved from $1.7M to $-37M — a 2322.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Inari Medical's operating scale or balance-sheet position.

Against Healthcare companies, NARI currently prints $-37M for EBIT, while the sector average sits near $22B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Inari Medical's growth, margins, and balance sheet.

A EBIT figure of $-37M for NARI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting NARI's EBIT ($-37M), review year-over-year change from $1.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.